Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

 

  Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

 

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

 

  About Astria Therapeutics:  

 

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

 

  

  

  Astria Contact:  

 

  Investor Relations and Media:  
Elizabeth Higgins
investors@astriatx.com  

 

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

 

  Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

 

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

 

  Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

 

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

 

  Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

 
  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  •  
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  •  

  About Astria Therapeutics:  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing

 

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Metals & Mining Virtual Investor Conference, held July 23 rd and 24 th are now available for online viewing.

 

   REGISTER AND VIEW PRESENTATIONS HERE   

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
FPX Nickel Provides Update on Normal Course Issuer Bid

FPX Nickel Provides Update on Normal Course Issuer Bid

 
 

 FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (" FPX " or the " Company ") is pleased to provide an update on its Normal Course Issuer Bid (" NCIB ") that was announced on December 2, 2024 . Since December 5, 2024 the Company has repurchased a total of 720,000 common shares (" Common Shares ") of the Company at an average price of $0.24 per share under the NCIB.

 
 

  FPX Nickel logo (CNW Group/FPX Nickel Corp.) 

 

The repurchased shares represent progress toward the Company's ability to acquire up to an aggregate of 5,000,000 Common Shares, representing approximately 2% of the Company's issued and outstanding shares, over the 12-month period ending December 5, 2025 . All shares repurchased under the NCIB have been cancelled.

 

Purchases under the NCIB continue to be executed through open market transactions on the TSX Venture Exchange, with the acquisition price determined by the prevailing market conditions at the time of each transaction. Cormark Securities Inc. is managing the NCIB on behalf of FPX.

 

  About FPX Nickel Corp.  

 

 FPX Nickel Corp.  is focused on the exploration and development of the Decar Nickel District, located in central British Columbia , and other occurrences of the same unique style of naturally occurring nickel-iron alloy mineralization known as awaruite.  For more information, please view the Company's website at   https://fpxnickel.com/.   

 

On behalf of FPX Nickel Corp.

 

"Martin Turenne"
Martin Turenne , President, CEO and Director

 

   Forward-Looking Statements   

 

  Certain of the statements made and information contained herein is considered "forward-looking information" within the meaning of applicable Canadian securities laws. These statements address future events and conditions and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators. Actual results could differ from those currently projected. The Company does not assume the obligation to update any forward-looking statement.  

 

  Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.  

 

SOURCE FPX Nickel Corp.

 

 

 

 Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/24/c8569.html  

 
 

 

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Juggernaut Mobilizes 2025 Exploration On Newly Discovered Big One 11 Km High-Grade Gold System That Remains Wide Open - Golden Triangle, B.C

Juggernaut Mobilizes 2025 Exploration On Newly Discovered Big One 11 Km High-Grade Gold System That Remains Wide Open - Golden Triangle, B.C

(TheNewswire)

 
        
  Juggernaut Exploration Ltd. 
                   
 

Vancouver, British Columbia July 23, 2025 TheNewswire - Juggernaut Exploration Ltd (JUGR.V) (OTCQB: JUGRF) (FSE: 4JE) ( the "Company" or "Juggernaut") is pleased to announce that it has mobilized for the 2025 surface exploration program aimed at identifying additional high-grade drill targets on the Big One property (the " Property "), Golden Triangle, British Columbia. This new discovery yielded assays up to 79.01 gt Au (2.54 ozt Au) and 3157.89 gt Ag (101.5 ozt Ag) from >200 gold-silver-copper rich polymetallic veins up to 8 m wide and striking for up to 500 m that remain open. These veins were identified along the newly discovered 11 km Highway of Gold surrounding the Eldorado gold system on the Big One property. The discovery is located in an area of glacial and snowpack abatement adjacent to the extensive gold-rich porphyry systems at Galore Creek. The 100 % controlled property covers 36,989 hectares in a Tier 1 geologic terrane with tremendous additional discovery potential.

Keep reading...Show less
Heritage Announces LIFE Offering and Provides Corporate and Exploration Update

Heritage Announces LIFE Offering and Provides Corporate and Exploration Update

 

(TheNewswire)

 
      
  Heritage Mining Ltd. 
             
 

  NOT   INTENDED   FOR   DISTRIBUTION   TO   UNITED   STATES   NEWS   WIRE   SERVICES   OR   FOR DISSEMINATION IN THE UNITED STATES  

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Metals & Mining Virtual Investor Conference Agenda Announced for July 23rd and 24th

Metals & Mining Virtual Investor Conference Agenda Announced for July 23rd and 24th

 

Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Metals & Mining Virtual Investor Conference to be held July 23 rd and 24 th .

 

Individual investors, institutional investors, advisors, and analysts are invited to attend.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×